INSTITUTIONAL BARRIERS TO BUSINESS ENTRY IN ADVANCED ECONOMIES
نویسندگان
چکیده
منابع مشابه
Business Cycle Linkages Among Major Advanced Economies
current policy issues involving interactions across national economies. Given that the global economy is in a synchronized slowdown in economic activity, the first two essays are devoted to an examination of the international business cycle linkages among the seven major advanced economies—hereafter called the Group of Seven (G-7) countries—and between the advanced and developing economies. The...
متن کاملBarriers to Business in India.PDF
Japanese companies in India are required to pay additional costs to avoid breakdown of machinery due to blackouts and voltage changes. The bad condition of roads inflicts damage on commodities during transportation. Transportation between Delhi and the South takes one week due to the lack of express highways. Economic losses are incurred because of the long transportation time and high gasoline...
متن کاملInstitutional determinants of investment in transition economies
Investment has been found to be a significant determinant of growth. This paper analyses the effects of institutions and transition progress on investment rates of transition economies since the collapse of the Socialist Bloc. Political institution is measured by the Freedom House’s Political Rights and Civil Liberties indexes; economic institution is proxied by the Index of Economic Freedom co...
متن کاملBarriers to Technology Adoption and Entry∗
A key feature of recent work on barriers to technology adoption is the assumption that monopoly rights of insiders are limited by the ability of industry outsiders to enter. This paper endogenizes the decision of a government to provide barriers to technology adoption alone or in combination with barriers to entry of outsiders. Using a political economy model, we find that a government provides...
متن کاملBiologic Drugs, Biosimilars, and Barriers to Entry.
Biologic drugs represent an important new category of drugs in the effort to improve health outcomes in this country. Yet, these cutting-edge drugs are often cost prohibitive, preventing access for many Americans. Recognizing the need for more affordable, generic substitutes for biologic drugs—or biosimilars—Congress recently created a biosimilars approval pathway that would enable these cheape...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Business Economics and Management
سال: 2013
ISSN: 1611-1699,2029-4433
DOI: 10.3846/16111699.2011.633348